Immunogenicity, reactogenicity and safety study of Pediarix, Hiberix and Prevenar 13 co-administered with two different formulations of GSK Biologicals' HRV vaccine (444563) in healthy infants 6-12 weeks of age.

Project Details

StatusActive
Effective start/end date7/07/176/07/21

Funding

  • GlaxoSmithKline: $71,568.00

Keywords

  • Biotechnology & Drug Development, Immunology